全文获取类型
收费全文 | 48811篇 |
免费 | 3564篇 |
国内免费 | 2468篇 |
专业分类
耳鼻咽喉 | 254篇 |
儿科学 | 1358篇 |
妇产科学 | 472篇 |
基础医学 | 11228篇 |
口腔科学 | 387篇 |
临床医学 | 3659篇 |
内科学 | 13529篇 |
皮肤病学 | 578篇 |
神经病学 | 1215篇 |
特种医学 | 620篇 |
外国民族医学 | 7篇 |
外科学 | 2107篇 |
综合类 | 6299篇 |
现状与发展 | 18篇 |
预防医学 | 7336篇 |
眼科学 | 385篇 |
药学 | 2466篇 |
13篇 | |
中国医学 | 852篇 |
肿瘤学 | 2060篇 |
出版年
2024年 | 47篇 |
2023年 | 611篇 |
2022年 | 1859篇 |
2021年 | 2146篇 |
2020年 | 1695篇 |
2019年 | 1477篇 |
2018年 | 1492篇 |
2017年 | 1466篇 |
2016年 | 1732篇 |
2015年 | 2040篇 |
2014年 | 2826篇 |
2013年 | 2990篇 |
2012年 | 2756篇 |
2011年 | 3235篇 |
2010年 | 2684篇 |
2009年 | 2437篇 |
2008年 | 2391篇 |
2007年 | 2529篇 |
2006年 | 2267篇 |
2005年 | 1997篇 |
2004年 | 1762篇 |
2003年 | 1534篇 |
2002年 | 1222篇 |
2001年 | 1185篇 |
2000年 | 961篇 |
1999年 | 861篇 |
1998年 | 754篇 |
1997年 | 770篇 |
1996年 | 627篇 |
1995年 | 631篇 |
1994年 | 594篇 |
1993年 | 473篇 |
1992年 | 354篇 |
1991年 | 302篇 |
1990年 | 269篇 |
1989年 | 244篇 |
1988年 | 231篇 |
1987年 | 167篇 |
1986年 | 142篇 |
1985年 | 287篇 |
1984年 | 180篇 |
1983年 | 134篇 |
1982年 | 120篇 |
1981年 | 98篇 |
1980年 | 68篇 |
1979年 | 58篇 |
1978年 | 51篇 |
1977年 | 31篇 |
1976年 | 31篇 |
1975年 | 6篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Micro‐evolution of the hepatitis B virus genome in hepatitis B e‐antigen‐positive carriers: Comparison of genotypes B and C at various immune stages 下载免费PDF全文
2.
3.
4.
Auda A. Eltahla Fabio Luciani Peter A. White Andrew R. Lloyd Rowena A. Bull 《Viruses》2015,7(10):5206-5224
The hepatitis C virus (HCV) is a pandemic human pathogen posing a substantial health and economic burden in both developing and developed countries. Controlling the spread of HCV through behavioural prevention strategies has met with limited success and vaccine development remains slow. The development of antiviral therapeutic agents has also been challenging, primarily due to the lack of efficient cell culture and animal models for all HCV genotypes, as well as the large genetic diversity between HCV strains. On the other hand, the use of interferon-α-based treatments in combination with the guanosine analogue, ribavirin, achieved limited success, and widespread use of these therapies has been hampered by prevalent side effects. For more than a decade, the HCV RNA-dependent RNA polymerase (RdRp) has been targeted for antiviral development. Direct acting antivirals (DAA) have been identified which bind to one of at least six RdRp inhibitor-binding sites, and are now becoming a mainstay of highly effective and well tolerated antiviral treatment for HCV infection. Here we review the different classes of RdRp inhibitors and their mode of action against HCV. Furthermore, the mechanism of antiviral resistance to each class is described, including naturally occurring resistance-associated variants (RAVs) in different viral strains and genotypes. Finally, we review the impact of these RAVs on treatment outcomes with the newly developed regimens. 相似文献
5.
Comparative safety study on severe anemia by simeprevir versus telaprevir‐based triple therapy for chronic hepatitis C 下载免费PDF全文
Eiichi Ogawa Norihiro Furusyo Eiji Kajiwara Hideyuki Nomura Akira Kawano Kazuhiro Takahashi Kazufumi Dohmen Takeaki Satoh Koichi Azuma Makoto Nakamuta Toshimasa Koyanagi Kazuhiro Kotoh Shinji Shimoda Jun Hayashi The Kyushu University Liver Disease Study Group 《Journal of gastroenterology and hepatology》2015,30(8):1309-1316
6.
D Gröne† R Treudler† EM de Villiers‡ R Husak† CE Orfanos† ChC Zouboulis†§ 《Journal of the European Academy of Dermatology and Venereology》2006,20(2):202-205
Cidofovir is an acyclic nucleoside phosphonate with broad-spectrum activity against DNA viruses, including human papilloma virus (HPV). However, data on the efficacy of cidofovir in an immunosuppressive setting remain contradictory. We report for the first time on the promotion of the healing of recalcitrant warts in a patient with myelodysplastic syndrome with intravenous cidofovir treatment. 相似文献
7.
MASAFUMI IKEDA SHIGETOSHI FUJIYAMA MOTOHIKO TANAKA MICHIO SATA TATSUYA IDE HIROSHI YATSUHASHI HIROSHI WATANABE 《Journal of gastroenterology and hepatology》2006,21(1):122-128
Background and Aim: This study investigated the clinical features of hepatocellular carcinoma in patients with sustained virological response to interferon for hepatitis C viral (HCV) infection. Methods: A total of 7715 patients with HCV infection were treated with interferon and followed up for more than 1 year after withdrawal of interferon in 64 Japanese hospitals and clinics between July 1988 and August 2001. Sustained virological response was obtained in 2515 (32.6%) patients. Of these 2515 patients, clinical data were collected for 38 patients in whom hepatocellular carcinoma developed. Sustained virological response was defined as HCV RNA negativity more than 6 months after the termination of interferon. Results: All patients were HCV RNA negative at the time of diagnosis of hepatocellular carcinoma. The median period until the detection of hepatocellular carcinoma was 4.7 years (range 1.4–9.0 years). There were significant improvements in hepatic function including serum albumin, aspartate aminotransferase, alanine aminotransferase, indocyanine green test, platelet count and histological activity grade in comparison with those before interferon therapy and at the onset of hepatocellular carcinoma. The maximum tumor size in patients without medical follow‐up for 1 year or more (median: 60 mm) was significantly larger than in patients who were periodically followed up for 6 months or less (median: 25 mm) (P = 0.002). Conclusions: The present findings emphasize the importance of regular medical follow up of patients with HCV infection, as even patients showing a sustained virological response to interferon and in whom hepatic function has improved have the potential to develop hepatocellular carcinoma. 相似文献
8.
采用免疫组织化学S-P法检测52例手术切除乳腺癌组织c-erbB-2蛋白和HSV-1、HSV-2表达情况。结果发现癌组织中c-erbB-2阳性34例(65.4%);HSV-1阳性38例(73.1%);HSV-2阳性15例(28.8%)。癌旁组织32例,阳性分别为3例(9.4%);12例(37.5%);2例(6.3%)。乳腺癌中c-erbB-2阳性率明显高于癌旁组织。乳腺癌及癌旁的HSV-1阳性率明 相似文献
9.
Active production of anti-human T-lymphotropic virus type I (HTLV-I) IgM antibody in HTLV-I-associated myelopathy 总被引:2,自引:0,他引:2
Kunihiko Nagasato Tatsufumi Nakamura Ohishi Kiyosumi Kohji Shibayama Masakatsu Motomura Ichinose Katsuhiro Mitsuhiro Tsujihata Shigenobu Nagataki 《Journal of neuroimmunology》1991,32(2):105-109
We investigated the presence of anti-human T-lymphotropic virus type I (HTLV-I) IgM in sera and cerebrospinal fluid from patients with HTLV-I-associated myelopathy (HAM) by Western blot analysis. Analyses of 36 serum samples revealed that most patients (31/36; 86.1%) had anti-HTLV-I IgM, whereas only four of 23 (17.4%) HTLV-I carriers had it. In studies of cerebrospinal fluid, anti-HTLV-I IgM was detected in 24 of 36 (66.7%) HAM patients, whereas none was detected in nine HTLV-I carriers. The differences were statistically significant (p less than 0.01). These results suggest that persistent active replication of HTLV-I occurs in the central nervous system as well as in the peripheral blood of HAM patients, and may contribute to the development of HAM. 相似文献
10.
Permissive herpes simplex virus (HSV) infection in tissue culture results in host cell destruction. Latent HSV infection in vivo occurs in neurons of peripheral sensory ganglia (PSG) and it therefore can not take place in neurons in which the virus has completed a lytic replication cycle similar to that present in vitro. Our hypothesis, based on experimental data and observations in humans, suggests that establishment of latent infection and reactivation of HSV-1 does not involve neuronal cell loss. Latency is established in neurons in which the virus does not replicate and is determined, in part, by the tissue levels of a herpes transactivating protein (Vmw65) that is a component of the viral tegument. We also suggest that reactivation of latent infection does not involve destruction of neurons and is due to replication of virus at the peripheral mucocutaneous tissues to where virus or viral DNA have been transported from the nervous tissue. Alternatively, reactivation is initiated in the PSG using a replication cycle which does not involve irreversible damage to neurons. This model explains the lack of damage to neurons which continue to serve as permanent reservoirs of latent virus for the entire life of the host. 相似文献